Generics BulletinBrazil’s Hypera does not intend to be left out of the race to compete with Ozempic (semaglutide) when generic rivals launch in its domestic market next year. Speaking during the firm’s full-year resul
Generics BulletinHypera Pharma’s board of directors has unanimously rejected a proposed merger with fellow Brazilian firm EMS only days after the initial offer due to a perceived undervaluation and strategic factors.